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Abstract: Background: The aim was to investigate the clinical significance of nestin immunohis-
tochemical expression in head and neck area lesions and to study its role in patient survival and
recurrence. Methods: 39 (44.3%) nasosinus, 37 (42%) major salivary gland (6 submandibular and
31 parotid) and 12 (13.6%) oral cavity lesions of paraffin-embedded samples were retrospectively
included. Results: The expression was categorized into grades, negative for 55 (62.5%) cases, grade
1 in 10 cases (11.4%), grade 2 in 12 cases (13.6%), and grade 3 in 11 cases (12.5%); 100% of pleo-
morphic adenomas were positive for nestin with grade 3 intensity, 100% of polyps and inverted
papillomas were negative (p < 0.001). The lowest estimate of disease-free-survival (DFS) was for
grade 1 expression, with 50 months, confidence interval (CI): 95% 13.3–23.9 months and the highest
for grade 3 expression, 167.9 months (CI: 95% 32.1–105 months; Log-Rank = 14.846, p = 0.002). ROC
(receiver operating characteristic) curves revealed that the positivity for nestin (+/−) in relation to
malignancy, presented a sensitivity of 50.98%, a specificity of 81.08%, with an area under the curve of
0.667 (p = 0.009). Conclusions: Nestin could be a useful marker to detect the presence of stem cells in
head and neck tumors that have a role in tumor initiation and progression.
Keywords: head and neck neoplasms; nestin; immunohistochemistry; recurrence
1. Introduction
Nestin is a class VI embryonic intermediary filament protein and has been shown to be
a marker of immature/stem cell-like tissue, such as the brain [1], arterial vessels [2], liver [3],
major [4] and minor [5] salivary glands, maxillary sinus mucosa [6] and oral mucosa [7,8].
A recent work has related nestin to the phenomenon of epithelial-mesenchymal transition
(EMT) and Wnt/beta-catenin signalling [9]. Malvi and Cols. [10] have found that, in mixed
primary liver tumors, the hepatocellular-colangiocellular variety were nestin-negative
while intermediate-cell variety carcinomas, showed immunoreactivity in most cases (92.3%),
which can be useful in tumor differential diagnosis. Intermediary filament (keratins,
vimentin and nestin) have been postulated to act as tumoral and metastasis development
effectors, following the “hallmarks of cancer” described by Hanahan and Weinberg, keeping
cell stemness through CDK5 inhibition [11,12].
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During embryogenesis, nestin is expressed in cellular migration and proliferation. By
contrast, in adult tissues nestin is restricted mainly to regenerative areas, being abundant
in progenitor cells derived from embryonic stem cells, which have the potential to develop
into neuroectodermal, endodermal and mesodermal lineages, indicating regenerative
potential [13]. It is intensely expressed in cancer cells with high metastatic capacity [14]
and, although it is demonstrated that nestin expression inhibition can reduce tumor cell
metastatic capacity [15], the metastatic mechanism of this protein in cancer development is
still not clear.
Nestin blockade has been shown to inhibit the proliferation of colorectal cancer cell
lines [16], migration, invasion and stemness of lung adenocarcinoma lines [14] and a
reduction in the 5-year survival rate has been verified in nestin-positive breast cancer
patients [17]. Nevertheless, studies in head and neck tumors are scarce. In a systematic
review by Curtarelli et al. in 2018 [18], only two studies were included [19,20].
Given the lack of studies on nestin expression in head and neck conditions, the
aim of this work is to investigate the clinical significance of nestin immunohistochemical
expression in head and neck area lesions (nasosinus, salivary gland and oral cavity) and to
study its role in patient survival and recurrence.
2. Materials and Methods
Study design: This is a retrospective observational study, designed according to
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recom-
mendations [21] and approved by the Galician Autonomous Committee of Ethics (reference
2019/271). Samples were retrieved from the registers of the University Hospital Complex
of Santiago de Compostela. All procedures were carried out with the understanding and
written consent of the subjects in accordance with the Declaration of Helsinki and its
subsequent amendments.
Sample selection and histological evaluation: a total of 88 paraffin-embedded samples
of benign and malignant conditions with a confirmed histopathological diagnosis were
included. Five µm of haematoxylin-eosin stained sections from all cases were histopatho-
logically analyzed and reviewed by two of the authors (JMSP and MPS) who adjusted the
diagnosis according to the international recommendations for histopathological analysis.
The clinical data of the patients and the characterization of the lesions (AJCC American
Joint Committee of Cancer 8th Ed. 2017) were collected in a pseudonymized database.
Immunohistochemical evaluation: immunohistochemistry was performed using a
rabbit monoclonal anti-nestin antibody EPR1301(2) (1:500 dilution, Abcam Cambridge, UK)
with an automatized equipment (Omnis, Agilent Dako, Santa Clara, CA, USA). In brief,
epitope retrieval was performed in 10 mM sodium citrate buffer (pH 9.0) using a water bath
for 40 min at 95–99 ◦C. Endogenous peroxidase was blocked using peroxidase-blocking
reagent (Agilent Dako, Santa Clara, CA, USA) for 5 min. Incubation with the primary
antibody (1/500) was performed at room temperature for 20 min and staining was revealed
with EnVision (20 min) and DAB (diaminobenzidine) 10 min) (Agilent Dako, Santa Clara,
CA, USA). Finally, slides were counterstained with HE for 15 min.
Immunohistochemically, only unequivocal cytoplasmic staining was considered posi-
tive. Results were evaluated semi-quantitatively attending to the following criteria: neg-
ative (Score 0) when no cells stained for nestin; weak (Score 1) when only scattered cells
(less than 10% were positive); moderate (Score 2) when positive cells represented 10 to 50%,
and strong (Score 3) when over 50% of the cells stained with the antibody. For statistical
purposes, nestin expression was also evaluated as negative (score 0) or positive (scores 1, 2
and 3). Stromal or vascular staining was not considered.
Statistical analysis: SPSS v.24.0 (IBM, Statistics, Armonk, NY, USA) was used for
statistical analysis. Results were described by mean and standard deviation and frequency
with percentages. The data were subjected to the chi-square and Kruskal–Wallis test to
study the relationships between the categorical variables. Kaplan–Meier curves were used
to study survival and Cox regression with hazard ratio to determine the role of nestin
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expression. ROC curves were made to estimate the diagnostic efficacy of nestin positivity
in malignancy. The significance level was established for p ≤ 0.05.
3. Results
3.1. Clinical and Histopathological Data
A total 88 patients were studied, 40 (45.5 %) women and 48 (54.5 %) men, with an
average age of 54.7 ± 18.9 years. The final distribution of the sample was 39 (44.3%)
nasosinus, 37 (42%) major salivary gland (6 submandibular and 31 parotid) and 12 (13.6%)
oral cavity lesions (Table 1).
Table 1. Distribution of categorical variables by Nestin expression analyzed through Kruskal–Wallis test.
Variable
Nestin Expression
Total p-Value0 1 2 3
Gender
Female 24 (60) 4 (10) 5 (12.5) 7 (17.5) 40 (45.5)
0.635Male 31 (64.6) 6 (12.5) 7 (14.6) 4 (8.3) 48 (54.5)
Origin
Nasosinus 33 (84.6) 2 (5.1) 4 (10.3) 0 39 (44.3)
0.001Salivary glands 18 (48.6) 6 (16.2) 3 (8.1) 10 (27) 37 (42)
Oral 4 (33.3) 2 (16.7) 5 (41.7) 1 (8.3) 12 (13.6)
Localization
Nasosinus 33 (84.6) 2 (5.1) 4 (10.3) 0 39 (44.3)
0.001
Parotid gland 16 (51.6) 6 (19.4) 1 (3.2) 3 (25.8) 31 (35.2)
Submandibular gland 2 (33.3) 0 2 (33.3) 2 (33.3) 6 (6.8)
Alveolar mucosa 3 (60) 0 2 (40) 0 5 (5.7)
Buccal mucosa 1 (50) 1 (50) 0 0 2 (2.3)
Floor of the mouth 0 0 1 (50) 1 (50) 2 (2.3)
Lip 0 0 1 0 1 (1.1)
Tongue 0 0 1 0 1 (1.1)
Retromolar trigone 0 1 0 0 1 (1.1)
Histological
type
Adenocarcinoma 4 (50) 2 (25) 1 (12.5) 1 (12.5) 8 (9.1)
<0.001
Carcinoma 16 (44.4) 6 (16.7) 11 (30.6) 3 (8.3) 36 (40.9)
Lymphoma 1 (33.3) 2 (66.7) 0 0 3 (3.4)
Inverted papilloma 14 (100) 0 0 0 14 (15.9)
Polyp 13 (100) 0 0 0 13 (14.8)
Pleomorphic adenoma 0 0 0 7 (100) 7 (8)
Warthin tumor 4 (100) 0 0 0 4 (4.5)
Mucoepidermoid
carcinoma 3 (100) 0 0 0 3 (3.4)
Malignancy No 30 (81.1) 0 0 7 (18.9) 37 (42) <0.001Yes 25 (49) 10 (19.6) 12 (23.5) 4 (7.8) 51 (58)
Death
No 42 (66.7) 2 (3.2) 8 (12.7) 11 (17.5) 63 (71.6)
<0.001Yes 13 (52) 8 (32) 4 (16) 0 25 (28.4)
Death by
lesion
No exitus 42 (66.7) 2 (3.2) 8 (12.7) 11 (17.5) 63 (71.6)
<0.001Yes by the lesion 8 (61.5) 2 (15.4) 3 (23.1) 0 13 (14.8)
Yes other reasons 5 (41.7) 6 (50) 1 (8.3) 0 12 (13.6)
Relapse No 40 (67.8) 3 (5.1) 7 (11.9) 9 (15.3) 59 (67) 0.038Yes 15 (51.7) 7 (24.1) 5 (17.2) 2 (6.9) 29 (33)
Total 55 (62.5) 10 (11.4) 12 (13.6) 11 (12.5) 88 (100)
Thirty-seven benign (42%) and 51 malignant (58%) lesions were included. The most
frequent histological type was carcinoma, with 36 cases (40.9%), followed by inverted
papilloma with 14 cases (15.9%) and nasosinus polyps with 13 cases (14.8%). A complete
description of different tumor subtypes can be found in Supplementary Information.
3.2. Immunohistochemical Expression of Nestin
Nestin staining in normal salivary glands was found to be limited to endothelium and
nerve fibers, but parenchymal cells, acinar or ductal, were completely negative except for
some myoepithelial cells, which were occasionally stained (Figure 1(A1)).
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tive in 81.1% of the cases, against 49% of the malignant ones (p < 0.001) (Figure 1B1 and 
1C1). In relation to the histological type, 100% of pleomorphic adenomas were positive 
for nestin with grade 3 intensity, 100% of polyps and inverted papillomas were negative 
(p < 0.001) and the rest of the histological varieties were positive in a variable pattern 
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Figure 1. No mal nasosinus mucosa (A1) showed nestin expr ssion restricted to vessels and concentrated under the
epithelium (A2). Inflammatory polyps (B1) showed the sa e staining pattern, consistent with its non-neoplastic nature
(B2). In inverted nasosinusal papillomas (C1), the proliferative epithelium was always completely negative (C2).
The expression was categorized into grades, negative for 55 (62.5%) cases, grade 1 in
10 cases (11.4%), grade 2 in 12 cases (13.6%), and grade 3 in 11 cases (12.5%). There were no
difference in terms of gender. Regarding origin, 84.6% nasosinus lesions were negative
compared to those from the salivary glan and oral origin, which were positive (in different
degrees) respectively, in 51.4% and 66.7% (p = 0.001). Benign lesions were negative in 81.1%
of the cases, against 49% of the malignant ones (p < 0.001) (Figure 1(B1,C1)). In relation to
the histological type, 100% of pleomorphic adenomas were positive for nestin with grade 3
intensity, 100% of polyps and inverted papillomas were negative (p < 0.001) and the rest of
the histological v rieties were positive in a variable pattern (Figure 2).
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Whartin (H1 and H2) tumor were always negative. From I to IV, an inset with higher magnification 
of adenocarcinoma (I), pleomorphic adenoma (II), adenoid cystic carcinoma (III) and squamous 
cell carcinoma (IV). 
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Figure 2. Two examples of poorly differentiated adenocarcinoma, one with extensive immunohistochemical stai ing
(A1 and A2) and another with no nestin expression (B1 and B2). Pleomorphic adenoma (C1 and C2) showed marked
and widespread staining for nestin both in the epithelial and mesenchymal components i all cases. In adenoid cystic
carcinomas (D1) nestin expression was limited to basal cells (D2). Squamous cell carcinomas demonstrated a wide range of
immunohistochemical staining with some cases strongly positive (E1 and E2) while others were almost completely negative
(F1 and F2). Finally, mucoepidermoid carcinomas (G1 and G2) and Whartin (H1 and H2) tumor were always negative.
From I to IV, an inset with higher magnification of adenocarcinoma (I), pleomorphic adenoma (II), adenoid cystic carcinoma
(III) and squamous cell carcinoma (IV).
3.3. Follow-Up: Mortality and Recurrence
The average follow-up period was 70.5 ± 70.6 months with a range of 1.4 to 280.4
months. 28.4% of the patients died (14.8% due to the tumor), with an overall survival of
43.7 ± 39.9 months with a range of 1.4 to 119.2 months, and the disease specific survival
of 38.1 ± 41.6 months, with a minimum of 1.4 months and a maximum of 113.6 months.
During the follow-up period, 33% of the l sions recurred, with a me n of 0.6 ± 1.3 re-
currences per patient, with a maximum of 9 per patient (adenocarcinoma being the most
recurrent variety). The disease-free survival was 39.8 ± 51.6 months, with a minimum of
2.2 months and a maximum of 235.3 months. An average time until the last recurrence
of 87.7 ± 74.2 months and an average period of recurrences of 38.8 ± 36.2 months were
recorded (Table 2).
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37.6 ± 43.3 21.9 ± 13.5 50 ± 56.8 – 0.791(1.4–73.8) (–100–143.9) (–91.1–191.1)
Number of
relapses
0.5 ± 1.3 1.3 ± 1.5 0.75 ± 1 0.27 ± 0.6
0.289(0.17–0.92) (0.18–2.4) (0.8–1.4) (–0.16–0.7)
Time until last
relapse
84.5–59.3 30.8 ± 6.1 117.9 ± 126
129.4 0.637(22.2–146.9) (–24.5–86.1) (–195–431)
Period of relapses 53.4 ± 45 13.8 ± 1.37 20.9 ± 16.9 54.52 0.470(6.1–100.6) (1.5–26.1) (–21–62.9)
* Global mean difference by analysis of variance (ANOVA) test. Multiple correlations by post-hoc Bonferroni test for groups of nestin
expression. * For age: Nestin-0 vs. Nestin-1, p = 0.001; Nestin-1 vs. Nestin-2, p = 0.003; Nestin-1 vs. Nestin-3, p = 0.043. ** For disease-free
survival: Nestin-1 vs. Nestin-2, p = 0.039.
In relation to the follow-up in terms of nestin expression (Tables 1 and 2), no deaths
occurred in patients with grade 3 expression, compared to 52% mortality in those who were
negative for nestin (p < 0.001). In relation to recurrence, the majority of cases are negative
(51.7%) compared to cases of intense grade 3 expression in which 6.9% (p = 0.038). Grade
1 expression is significantly associated with older patients (76.3 ± 9.4 years, confidence
interval (CI): 95% 69.5–83 years, p = 0.001). Disease-free survival was significantly lower
for lesions with grade 1 expression (15.6 ± 9, CI: 95% 7.2–24 months) than for grade 2
(96 ± 85.5, CI: 95% –10.1–202.2 months) (p = 0.001) (Table 2).
3.4. Survival Analysis
Kaplan–Meier curves showed that mortality was not a significant factor for the expres-
sion of nestin, nevertheless when pleomorphic adenomas were excluded, we considered
only the first 60 months of follow-up (5 years), and nestin immunohistochemical expression
was not graded and only considered as positive vs. negative, survival was worse for posi-
tive nestin cases, 30.41 ± 4.27 months (confidence interval (CI) 95% 22.04–38.77 months) vs.
negative cases with 44.48 ± 4.04 months (IC 95% 36.56–52.40 months) (Log-Rank = 3.867,
p = 0.049) (Figure 3A). For relapses, the lowest estimate of DFS was for grade 1 expression,
with 50 months, CI: 95% 13.3–23.9 months and the highest for grade 3 expression, 167.9
months, CI: 95% 32.1–105 months (Log-Rank = 14.846, p = 0.002) (Figure 3B).
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Figure 3. (A) Kaplan Meier survival curve designed by excluding pleomorphic adenomas and considering nestin immuno-
histochemical expression during the first 5 years of follow-up. (B) Kaplan Meier survival curve for relapse based on fully
graded nestin expression. By means of Cox regression, we verified that the Hazard Ratio for grade 1 expression is 4.577
(confidence interval (CI): 95% 1.802–11.626, p = 0001). For a model adjusted by location, sinus lesions are protective for
recurrence (hazard ratio (HR) = 0.210, CI: 95% 0.070–0.627, p = 0.005) (Table 3).
Table 3. A univariate logistic regression analysis was p rformed to determine the un variat hazard ratio (HR) for Relapse.






(95% CI) p Value
Adjusted HR
(95 % CI) p Value
Nestin
Negative Vs 1 4.577 (1.802–11.626) 0.001 8.918 (2.71–305.62) <0.001
Negative Vs 2
Negative Vs 3
1.023 (0.332–3.158) 0.968 1.347 (0.354–5.118) 0.662
0.546 (0.122–2.433) 0.427 0.899 (0.151–5.356) 0.907
Location
Nasal/Sinus Vs trigone 0.034 (0.03–0.389) 0.006 0.210 (0.070–0.627) 0.005
Parotid Vs trigone 0.013 (0.001–0.160) 0.001 0.246 (0.020–2.966) 0.270
Submaxilla Vs trigone 0.010 (0–0.236) 0.004 2.497 (0.413–15.087) 0.319
Alveolar ridge Vs
trigone 0.086 (0.006—1.270) 0.074 0 0.992
Buccal mucosa Vs
trigone 0 0.991 0 0.994
Floor of mouth Vs
trigone 0 0.991 0 0.963
Lip Vs trigone 0 0.956 0 0.995
Tongue Vs trigone 0 0.994 4.405 (0.344–56.384) 0.254
3.5. Diagnostic Yield
The study using ROC (receiver operating characteristic) curves revealed that the
positivity for nestin (+/−) in relation to malignancy (yes/no), presented a sensitivity of
50.98%, a specificity of 81.08%, with an area under the curve of 0.667 (p = 0.009) (Figure 4).
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Figure 4. ROC (receiver operating characteristic) curve based on the diagnostic capacity of nestin
positivity in relation to malignancy. The area under the curve was 0.667 (p = 0.009).
4. Discussion
We have found a positivity for nestin in head and neck region lesions of 37.5% globally,
remaining negative in all inflammatory lesions (polyps) and inverted papillomas) and in
51% of malignant tumour lesions. The malignant lesions in the oral cavity reached a level of
positivity of 66.7% significantly, although in relation to intensity, 100% of the pleomorphic
adenomas of the salivary gland were grade 3. Mortality and recurrence were higher for
negative cases and similarly, the DFS was significantly lower i the cases of grade 1 nestin
in relation to the most intense grades. The hazard ratio for recurrence was 4.577 for cases
with mild nestin expression (grade 1) and 8918 when we adjusted the model by location.
The inter ediate filament pr tein nestin, initially considered a marker for neural
stem cells, is extensively expressed in progenitor cells derived from embryonic stem cells,
which have the ability to become multi-linear [13]. Since it is not expressed in mature
elements and that terminal cell differentiation is associated with loss of immunoreactivity
to this protein, immunohistochemical assessment of nestin expression might be useful to
differentiate between mature and immature cells/populations. Some reports have claimed
its value to differentiate between benign and malignant lesions [22,23]. Little has been
studied about the expression in head and neck entities [18,24]. In a recent meta-a alysis
conducted by Han et al. [24], on the prognostic value of ALDH1 and nestin in advanced
cancers (breast, colon, colorectal, cervical, ovarian, skin and hepatocellular), no head and
neck study was included.
It has been reported that expression of nestin in the soft tissues of patients with uni-
or bilateral cleft lip may indicate a potential increase of tissue regeneration [25]. Also,
nestin staining may even indicate that human oral mucosa can be an effective source for
hard tissue regeneration [7] and tooth tissue engineering applications [8]. In relation to
the maxillary sinus, the regenerative potential of the Scheneiderian membrane has been
postulated, associated with the presence of progenitor cells that express nestin [6,26], but
the authors have not f nd any studies that analyse expression in lesions located in the
nasosinus region. Luo et al. [19], studied the expression of embryonic stem cell markers
(SOX2, OCT4 and NANOg) in nasopharyngeal lesions, with the aim of analysing EMT.
They foun th t nestin expr ssion was completely absent in non- ncerous epithelium
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and tumor cells, while it was strongly stained in the cytoplasm of endothelial cells in
cancerous tissues, as 32 out of 48 tumors (66.7%) showed cytoplasmic positivity for nestin
in the endothelium, frequently located in the invasive front. We have not been able to
reproduce these findings and, in our cases, endothelial expression was wide and not
limited to the tumor front. Tumor cells exhibiting similar characteristics to cancer stem
cells (CSC) significantly correlated with nestin staining on the invasive front, so Luo
et al. [19] postulated that vascular endothelial cells expressing nestin may represent the
niche of SCC in nasopharyngeal carcinomas. They found no association of nestin with
survival. In the present study we have found the same results (Figure 1), being totally
negative for inflammatory lesions and with variable positivity in tumor lesions, mainly at
endothelial level.
Mascolo et al. [20] studied the expression of molecules associated with resistance to
DNA damage (poly(ADP-ribose) polymerase 1 (PARP-1) and chromatin assembly factor-1
(CAF-1)/p60) and of stem cell markers (nestin) in oral squamous cell carcinoma (OSCC)
samples. They found that a PARP-1-high/CAF-1-p60-high/nestin-high phenotype char-
acterized OSCC with the worst prognosis, recurrence, metastasis, and death (all HPV-
negative). Nestin was particularly expressed in OSCC metastases. The sensitivity of nestin
(high expression) to predict at least one adverse event was 100% with a specificity of 56%.
In our cohort, we included 11 OSCC and one mucoepidermoid carcinoma of the oral cavity.
In the OSCC, 27.3% of the samples were negative for nestin, and expression was intense
(grades 2 and 3) in 54.6% of the cases, but we could not establish a relationship with mor-
tality, although to the limited number of cases. In relation to the oral cavity, Kuk et al. [27]
found that, in a series of 39 oral melanomas (6 in situ and 36 invasive), found the same
as Mascolo et al. [20], this is a relationship of nestin expression (intensity and proportion)
and disease progression, as well as a worse prognosis (Hazard ratio 3.59 for intensity
and 4.05 for proportion). Ravindran and Devaraj [28] studied the expression pattern and
prognostic significance of two neural stem cell markers, nestin and musashi-1, in oral
cancer. A gradually increased expression of nestin was found along the transformation
stages of oral cancer. Association with higher stage and poor differentiated status of oral
carcinomas was identified with nestin or musashi-1 positive lesions. In the same way, a
highly significant correlation with poorer survival was detected when both markers were
present in the samples.
Regarding salivary gland conditions, Yanai et al. [29] described the expression of
nestin in normal glandular tissue and tumors. In normal salivary gland tissue, nestin was
detected in the endothelium and nerve fibres [30]. Although most of the luminal and ablu-
minal cells were negative, a few smooth muscle actin-positive myoepithelial cells α from
the acini or intercalated ducts expressed nestin. In all pleomorphic adenomas (n = 11), the
myoepithelial cells in both the ductal structure and the mesenchymal area showed diffuse
staining for nestin, similarly to the grade 3 nestin expression in all pleomorphic adenomas
found in the present study. They found no negative adenocarcinomas; however, in our
series, 4 (50%) were negative. All mucoepidermoid carcinomas and Whartin’s tumors were
negative in both studies, which may serve as a differential diagnostic guide. As previously
pointed out, pleomorhic adenomas are the tumor type with the most consistent immuno-
histochemical expression of nestin. Immunohistochemical expression of some stem cell
markers, such as the stem cell marker B cell-specific Moloney murine leukemia virus inte-
gration site 1 (Bmi-1) has been reported as an indication of early malignant transformation
in pleomorphic adenoma [31]. Nevertheless, none of our cases have behaved aggressively,
indicating that nestin is not a marker of malignant transformation in this neoplasm. It
is well known that pleomorphic adenomas are characterized by variable epithelial and
stromal components in a diversity of patterns. There is undoubtable histopathologically,
ultrastructural, immunohistochemical, and molecular evidence to suggest that the mes-
enchymal elements and the epithelial cells share the same origin [32]. In some areas this
neoplasm demonstrates a transitional phenotype with cells showing both epithelial and
mesenchymal features, which provides evidence for epithelial-mesenchymal transition as
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the basic principle of the tissue heterogeneity in pleomorphic adenomas [33]. Consonant
with these findings, immunohistochemical overexpression of nestin in pleomorphic adeno-
mas could be interpreted as a sign of this phenomenon instead of being related with the
clinical outcome of the neoplasm. Similar results were obtained by Yanai et al. [29] but they
did not associate it with the epithelial mesenchymal transition phenomenon. Our results
were also similar in adenoid cystic carcinoma, in which expression was strong and constant
in peripheral myoepithelial cells, and Warthin tumor and mucoepidermoid carcinoma,
both of them completely negative. The role of nestin in the epithelial-mesenchymal transi-
tion has already been reported in different contexts [34] and this could represent another
example of this function.
In our series we have not been able to demonstrate immunohistochemical expression
in any benign neoplasm, except for pleomorphic adenomas, in which it seems to be related
with the epithelial-mesenchymal transition and not with the benign or malignant character
of the lesion. Instead, malignant tumors have shown different grades of nestin immune
expression and, independent of its degree, it could be helpful to assess the malignant
character of a lesion in small biopsies. Although overall nestin expression does not seem to
be correlated with survival (since in this study all the patients with malignant tumors had
died during the large follow-up period), tumor relapsing is associated with nestin staining.
Moreover, when pleomorphic adenomas were excluded and nestin immunohistochemical
expression was not graded and only considered as positive vs. negative, survival was
worse for cases positive for nestin (p = 0.049). In head and neck tumors, the vast majority of
the stem cells are found within a 100 µm radius of a blood vessel, suggesting the existence
of a perivascular niche [35]. It could be argued that in advanced aggressive tumors
neoplastic growth overpass their vascular growth capacity, thus limiting the presence or
immunohistochemical ability to detect stem cells in some cases. Moreover, tumoral stem
cells have proved to be important for tumor development and progression, as well as
invasion, chemotherapy resistance, relapses and metastatic dissemination [36] but it is not
known if they are always present in the same amount in every step of tumor development
or if immunohistochemistry would be effective to detect them after chemotherapy and
radiotherapy. Based on the results of recurrence and death, it is our opinion that nestin
could be used generally to stratify head and neck cancers. No association has been observed
between nestin expression and gender, but it was more commonly expressed in tumors
from elderly patients. These results are difficult to interpret because of the different tumor
types included in the study and the low number of some of them. More studies including
a significant number of cases from each tumoral type would be needed to clarify this
issue. Nevertheless, our results confirm that nestin could be a useful marker to detect
the presence of stem cells in head and neck tumours, and in fact they have been earlier
demonstrated in some types of neoplasm in the area, which may have relevant implications
in the management of these neoplasms due to their role in tumor initiation and progression.
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